Abstracts tagged "Biologicals"

Abstract Number: 1237 • ACR Convergence 2020
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
Anthony Sebba¹, Jian Han² and Shalini V. Mohan², ¹Arthritis Associates, Palm Harbor, Tampa, FL, ²Genentech, South San Francisco, CA
Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
Abstract Number: 1428 • ACR Convergence 2020
The Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Matthew J. Koster¹, Kenneth Warrington¹, Jian Han² and Shalini V. Mohan², ¹Mayo Clinic, Rochester, MN, ²Genentech, South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) has been proven to be safe and effective for the treatment of giant cell arteritis (GCA) in 2 randomized controlled trials; however,…
Abstract Number: 1827 • ACR Convergence 2020
Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Anca Askanase³, Ed Vital⁴, Joan Merrill⁵, Rubana Kalyani⁶, Gabriel Abreu⁷, Lilia Pineda⁶ and Raj Tummala⁶, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³Columbia University College of Physicians and Surgeons, New York, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Objectives of long-term SLE management are not only to reduce disease activity, but also to prevent flares and minimize exposure to oral corticosteroids (OCS),…
Abstract Number: 0058 • ACR Convergence 2020
Drug Retention and Discontinuation of Biological DMARDs and Novel Small Molecules: Data from the Singapore National Biologics Registry
Li Wearn Koh¹, Man Hua Aw², Preeti Dhanasekaran³, Rosa Lim Mui San¹, Stephanie Wong⁴, Xanthe Chua⁵, Wei Joo Choy¹, Manjari Lahiri⁶ and Siaw Ing Yeo², ¹Tan Tock Seng Hospital, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, Singapore, ⁴Clinical Research and Innovation Office, Tan Tock Seng Hospital Singapore, Singapore, Singapore, ⁵Tan Tock Seng Hospital, Singapore, Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore
Background/Purpose: To describe drug retention rate and reasons for discontinuation of biological disease modifying anti-rheumatic drugs ( bDMARD) and novel small molecules in patients from…
Abstract Number: 0232 • ACR Convergence 2020
Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN
Christof Specker¹, Martin Aringer², Gerd Burmester³, Johannes Gerlach⁴, Michael Hofmann⁵, Herbert Kellner⁶, Frank Moosig⁷, Hans-Peter Tony⁸ and Gerhard Fliedner⁹, ¹Clinic Essen-Mitte, Essen, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, ³Charité University Hospital Berlin, Berlin, Germany, ⁴Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁵Chugai, Frankfurt am Main, Germany, ⁶Rheumatology and Gastroenterology Specialty Practice, Munich, Germany, ⁷Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, ⁸Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ⁹Rheumatology Practice, Onsabrück, Germany
Background/Purpose: RA increases a patient’s systemic inflammatory burden, which has been associated with development of chronic kidney disease (CKD), especially in patients with comorbid hypertension,…
Abstract Number: 0359 • ACR Convergence 2020
Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Soumya Chakravarty², Robert McLean³, Taylor Blachley³, Toana Kawashima⁴, Iris Lin⁵, Jonathan Uy⁶, Arthur Kavanaugh⁷ and Alexis Ogdie⁸, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Janssen Scientific Affairs, LLC, Horsham, ⁷UC San Diego Health System, San Diego, CA, ⁸Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Axial disease in psoriatic arthritis (PsA) has been reported to occur in anywhere from 25% to 75% of PsA patients (pts). It can be…
Abstract Number: 0556 • ACR Convergence 2020
Recent Use, Missed Doses and Discontinuation of Infliximab in New-users: Comparisons of Biosimilar and Originator Exposures
Cristiano Moura¹, Jeffrey R Curtis², Denis Choquette³, Gilles Boire⁴, Vivian Bykerk⁵, Carter Thorne⁶, Walter Maksymowych⁷, Peter Lakatos¹, Larry Svenson⁸, Laura Targownik⁵, Waqqas Afif¹ and Sasha Bernatsky⁹, ¹McGill University, Montreal, Canada, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Institut de Rhumatologie de Montréal, Montreal, Canada, ⁴Universite de Sherbrooke, Sherbrooke, Canada, ⁵University of Toronto, Toronto, Canada, ⁶Ontario Rheumatology Association, Aurora, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸University of Alberta, Edmonton, Canada, ⁹The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Biosimilar infliximab offers a potentially lower‐cost treatment option compared to its bio‐originator. However, uptake of biosimilars in general in North America has been slow.…
Abstract Number: 0799 • ACR Convergence 2020
Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD
Renske Hebing¹, Wouter Bos¹, Mike Nurmohamed² and Bart van den Bemt³, ¹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Medication non-adherence in rheumatoid arthritis (RA) is associated with disease flares, increased disability and increased costs. Electronic Monitoring Feedback (EMF) to improve adherence has…
Abstract Number: 0849 • ACR Convergence 2020
Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials
Joan Merrill¹, Kenneth Kalunian², Richard Furie³, Kevin Winthrop⁴, Patricia Primakov⁵, Lilia Pineda⁶, Gabriel Abreu⁷ and Raj Tummala⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²School of Health Sciences, University of California, La Jolla, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Oregon Health & Science University, Portland, OR, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In the phase 2 MUSE and phase 3 TULIP-1 and TULIP-2 trials, treatment with anifrolumab, a monoclonal antibody to the type I interferon receptor,…
Abstract Number: 0909 • ACR Convergence 2020
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Iain McInnes¹, Philip Mease², Dafna Gladman³, Laura Coates⁴, Peter Nash⁵, Alexis Ogdie⁶, Frank Behrens⁷, Philippe Goupille⁸, Arthur Kavanaugh⁹, Ruvie Martin¹⁰, Erhard Quebe-Fehling¹¹ and Corine Gaillez¹¹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Oxford, Oxford, United Kingdom, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸CHU Tours, department of rheumatology, Tours, France, ⁹Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
Abstract Number: 1335 • ACR Convergence 2020
Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Dominic Seet¹, Li Wearn Koh², Preeti Dhanasekaran³, Man Hua Aw⁴, Rosa Lim Mui San², Siaw Ing Yeo⁴ and Manjari Lahiri¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, Singapore, ⁴Singapore General Hospital, Singapore, Singapore
Background/Purpose: To describe the demographic and clinical characteristics of patients with inflammatory arthritis (IA) initiating biologic disease modifying anti-rheumatic drugs (bDMARD) who use complementary and…
Abstract Number: 1429 • ACR Convergence 2020
An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US
Kathryn Starzyk¹, Kimberly Milberg¹, Ashish Deshpande¹ and Gary Curhan¹, ¹OM1, Inc, Boston, MA
Background/Purpose: The mainstay of treatment for vasculitis has been corticosteroids and other cytotoxic and immunosuppressive medications (e.g., cyclophosphamide, methotrexate) to promptly achieve and maintain remission.…
Abstract Number: 1828 • ACR Convergence 2020
Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials
Eric Morand¹, Richard Furie², Ian Bruce³, Ed Vital⁴, Maria Dall'Era⁵, Emmanuelle Maho⁶, Lilia Pineda⁷ and Raj Tummala⁷, ¹Monash University, Melbourne, Australia, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, ³Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg
Background/Purpose: SLE is a heterogeneous autoimmune disease with clinical manifestations across multiple organ systems. In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab treatment resulted…
Abstract Number: 0084 • ACR Convergence 2020
Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort
Natalia Cabrera¹, Vannia Valinotti², Gabriela Avila-Pedretti¹, Sonia Cabrera², Patricia Melgarejo³, Zoilo Morel⁴, Lourdes Roman², Pedro Babak⁴, Rodrigo Acosta², Romina Glitz⁴, Darwin Cordovilla⁵, Roger Rolon⁴, Magali Zanotti-Cavazzoni¹, Marco Antonio Franco Britos⁶, Marcos Vazquez², Pedro Delgadillo⁴, Isabel Acosta², María del Carmen Martinez⁴, Gabriel Elizaur⁴, María Teresa Romero⁴, Ernesto Paredes⁴, Paloma de Abreu¹ and Leticia Segovia⁷, ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Hospital de Clínicas, Asunción, Paraguay, ³Hospital IPS, Villa Rica, Paraguay, ⁴Hospital Central del Instituto de Previsión Social, Asunción, Paraguay, ⁵Instituto Nacional de Reumatología, Montevideo, Uruguay, ⁶Instituto de Previsi�n Social, Asunci�n, Central, Paraguay, ⁷Hospital del IPS, Asunción, Paraguay
Background/Purpose: The Paraguayan-Uruguayan cohort of patients with rheumatic inflammatory diseases (BIOBADAGUAY), collect clinical and epidemiological information on adults and children patients receiving biological therapies (BT).…
Abstract Number: 0233 • ACR Convergence 2020
Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients
C. Fernandez-Diaz¹, Santos Castañeda², Rafael Melero³, Francisco Miguel Ortiz Sanjuan⁴, Antonio Juan-Mas⁵, Carmen Carrasco Cubero⁶, Raquel Almodovar⁷, Sebastian Rodriguez-Garcia⁸, C. Aguilera-Cros⁹, Ignacio Villa¹⁰, S. Ordoñez¹¹, Enrique Raya¹², C. Ojeda¹³, Manuel Jose Moreno-Ramos¹⁴, Gema Bonilla¹⁵, Susana Romero-Yuste¹⁶, Ana Ruibal-Escribano¹⁷, Jose Luis Andreu Sanchez¹⁸, R. Exposito¹⁹, Javier Loricera²⁰, Natalia Mena-Vazquez²¹, Ana Urriticoechea²², C. Peralta²³, Luis Arboleya²⁴, Francisco Javier Narváez²⁵, O. Maiz²⁶, Julia Fernandez Melon²⁷, P Vela²⁸, Ivan Castellvi²⁹, I. Cabezas³⁰, Alejandra Lopez Robles³¹, Patricia Carreira Delgado³², Juan M. Blanco-Madrigal³³, N. Del-val-del-amo³⁴, E Salgado³⁵, B. Garcia-magallon³⁶, Cristina Hidalgo Calleja³⁷, Mireia Corbeto Lopez³⁸, A. Perez³⁹, S. Castro⁴⁰, Juan Ramón De dios⁴¹, Andrea García Valle⁴², R Lopez⁴³, Angel García Aparicio⁴⁴, EC Cervantes⁴⁵, C Gonzalez⁴⁶, N Alvarez-Rivas⁴⁷, L. Perez⁴⁸, Miguel Ángel González-Gay⁴⁹ and Ricardo Blanco⁵⁰, ¹H. Marqués de Valdecilla, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³CHU. VIgo, Vigo, Spain, ⁴Rheumatology Department, HUP La Fe, Valencia, Spain, ⁵Son Llàzer University Hospital, Mallorca, Spain, ⁶H. Mérida, Mérida, Spain, ⁷Fundación Alcorcón University Hospital, Madrid, ⁸La Princesa University Hospital, Madrid, Spain, ⁹H.Virgen del Rocio, Sevilla, Spain, ¹⁰H. Torrelavega, Santander, Spain, ¹¹H. Arnau Vilanova, LLeida, Spain, ¹²San Cecilio Clinic Universitary Hospital, Granada, Spain, ¹³H. Virgen de la Macarena, Sevilla, Spain, ¹⁴Arrixaca University Hospital, Murcia, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶H Pontevedra, Coruna, Spain, ¹⁷Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹⁹H. Laredo, Laredo, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Hospital Regional Universitario de Málaga, Málaga, Spain, ²²Can Misses, Ibiza, Spain, ²³H. Clinico Zaragoza, Zaragoza, Spain, ²⁴H. Oviedo, Oviedo, Spain, ²⁵Hospital Bellvitge, BARCELONA, Spain, ²⁶H. Donosti, Donosti, Spain, ²⁷H. Son Espases, Mallorca, Spain, ²⁸H Alicante, Alicante, Spain, ²⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³⁰H. Río Ortega, Valladolid, Spain, ³¹H. León, León, ³²H. 12 de octubre, Madrid, Spain, ³³Basurto University Hospital, Bilbao, Spain, ³⁴Complejo Hospitalario de Navarra, Pamplona, Spain, ³⁵CHU Ourense, Ourense, Spain, ³⁶H. Huesca, Zaragoza, Spain, ³⁷Hospital Universitario Salamanca, Salamanca, Spain, ³⁸Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, ³⁹H. Puerta del Mar, Cadiz, Spain, ⁴⁰H. Joan XXIII, Tarragona, Spain, ⁴¹H. Alava, Alava, Spain, ⁴²H. Palencia, Palencia, Spain, ⁴³H. Negrin, Las Palmas, Spain, ⁴⁴H. Mostoles, Madrid, Spain, ⁴⁵H. Santiago de compostela, Santiago, Spain, ⁴⁶H. Valladolid, Valladolid, Spain, ⁴⁷H. S Agustin, Aviles, Spain, ⁴⁸Hospital Universitario Virgen de las Nieves, Granada, Spain, ⁴⁹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: To assess the efficacy of abatacept (ABA) in Rheumatoid Arthritis (RA) patients with Interstitial Lung Disease (ILD) (RA-ILD).Methods: Observational multicenter study of RA-ILD patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].